Small Cell Lung Cancer (SCLC) research hub
9 indexed studies · 3 currently recruiting
- active not recruitingPHASE2
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
This study is looking into a new treatment called tarlatamab for small cell lung cancer (SCLC). It aims to see how well it works and how safe it is for people whose cancer has progressed after other treatments.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study).”
This study looks at a new combination of two drugs, Lurbinectedin and Pembrolizumab, for people with small cell lung cancer that has come back. It aims to find the safest dose and see how well the combination works.
Spain - recruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
This study is looking into new ways to treat a serious type of lung cancer called small cell lung cancer. It combines standard chemotherapy with a new drug, tiragolumab, and an existing cancer drug, Tecentriq, to see if this mix works better than current treatments.
Greece · Italy · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)
This study looks at new ways to treat small cell lung cancer that has come back. It compares a drug called lurbinectedin, alone or with irinotecan, against standard treatments to see which helps patients live longer and clearer of cancer.
Poland · France · Germany - active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
United States · Argentina · Australia - recruiting
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
This study looks at how a lung cancer medicine called Tislelizumab works in real-life patients in Germany and Austria. It checks how well people do, how safe the medicine is, and their quality of life over up to five years.
Austria · Germany - authorisedTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
This study is testing a new drug, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to standard treatments to see if it works better and how it affects patients' lives.
Belgium · Czechia · Denmark